- Details
- Josh Meeks discusses the bladder cancer data from the ASCO GU 2019 meeting that is compelling from the perspective of urologists in this conversation with Alicia Morgans. Biographies: Josh J. Meeks, MD, PhD, Assistant Professor of Urology and Biochemistry and Molecular Genetics at Northwestern University Feinberg School of Medicine, Chicago Illinois Alicia Morgans, MD, MPH , Associate Professor of...
|
- Details
- Sia Daneshmand discusses the history of fast-tracked and streamlined post-operative cystectomy care for patients and associated improved outcomes in his conversation with Ashish Kamat. He details the development of the ERAS protocol and the significant milestones that have been realized in this journey to improved patient outcomes after cystectomy. Biographies: Siamak Daneshmand, MD Dr. Sia Danesh...
|
- Details
- Thomas Powles discusses the current state of immunotherapy in the treatment of muscle-invasive bladder cancer (MIBC) specifically in the second-line after cisplatin-based chemotherapy with Chuck Ryan. He discusses the recent learnings that immunotherapy offers a long-term durable response in 10 - 20% of the cisplatin-eligible patient population who are biomarker positive. They discuss ongoing clin...
|
- Details
- Jaime Landman is the Co-Director along with Zhamshid Okhunov, also of UCI, at the Engineering and Urology Society meeting, taking place during the AUA 2019 meeting in Chicago on May 5. One of our major highlights of this meeting will be the CEO Roundtable. The theme of the 2019 CEO roundtable is the successful translation of ideas into technology addressing unmet medical needs. Joining the roundta...
|
- Details
- Kala Sridhar provides a state of the-state in the contemporary understanding of upper tract disease, recent clinical trial findings and the impact of those trials on clinical practice treatment. Upper tract urothelial cancer (UTUC) accounts for approximately 5 - 7% of all urothelial cancers. At presentation about 60% of patients demonstrate invasive and/or locally advanced disease compared to abou...
|
- Details
- Simpa Salami, MD discusses the role of MRI in risk stratifying patients with prostate cancer. MRI has revolutionized the ability to detect aggressive prostate cancer but it is still possible that patients who have a negative MRI still have aggressive cancer. Up to 10-15% of patients may have aggressive prostate cancer despite negative findings on MRI. Dr. Salami addresses why these patients may ha...
|
- Details
- Jean Hoffman-Censits joins Alicia Morgans and shares details on the Johns Hopkins women’s bladder cancer program. This program is created in recognition of the pathway that women frequently take in the diagnosis of their bladder cancer. We often see a delay in the diagnostic process of bladder cancer in women compared to men. This delay in diagnosis leads to what is thought to be stage migration....
|
- Details
- Peter Black, MD discusses the challenges in both the diagnosis and treatment of UTUC. First, Dr. Black mentions the difficulty in obtaining adequate tissue for confirmation of diagnosis and to risk stratify patients. Traditionally diagnosis has been made based on imaging alone due to the challenges with obtaining biopsies leading to overtreatment for many patients. Due to the inability to appropri...
|
- Details
- Piyush Agarwal reflects on a debate at the EAU 2019 where he debated Seth Lerner, MD who is a preeminent urologist in bladder cancer. Dr. Lerner was favoring open surgery and Dr. Agarwal was favoring robotic surgery for the purpose of the debate as he conveys the positioning of the arguments with Charles Ryan. If you look at the robotic literature in urologic cancers, there is no evidence of any o...
|
- Details
- Maria De Santis discusses challenges in immunotherapy approaches for urothelial cancer with Alicia Morgans. One of the key challenges is understanding if the clinical trial data is translatable in daily practice due to the fact that most patients presenting with urothelial cancer are elderly. These patients tend to be over 70 years of age, have impaired renal function and decreased performance sta...
|
